Trial Profile
A Safety and Efficacy Study of a Single Center, Open-label, Single Arm About the Gene Correction of HBB in Patient-specific iHSCs Using CRISPR/Cas9 That Intervent Subjests With β-thalassemia Mutations
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 06 Jan 2021
Price :
$35
*
At a glance
- Drugs CRISPR/Cas9 modified human haematopoietic stem cell therapy-Allife Medical Science and Technology (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Sponsors Allife Medical Science and Technology
- 13 Nov 2018 New trial record